Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.

0
254
Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.


Priveterra Acquisition Corp. (PMGM) Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.

Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and, after the consummation of its pending business combination (the “Business Combination”) and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (“New AEON Common Stock”) and New AEON warrants to be listed on NYSE American LLC (“NYSE”) upon the Business Combination with AEON Biopharma, Inc., (“AEON”) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc.

Trading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol “AEON” for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occur on July 21, 2023, subject to satisfaction or waiver of standard, customary closing conditions.

As of July 17, 2023, Priveterra’s public stockholders holding 1,681,348 shares, out of a total of 2,002,272 shares, of Class A common stock validly elected to redeem their public shares for a full pro rata portion of the trust account holding the proceeds from Priveterra’s initial public offering, leaving 320,924 shares remaining. The redemption price as of July 17, 2023 is approximately $10.62.

Priveterra will be automatically accepting requests by stockholders to withdraw their previously submitted redemption requests until 5:00 p.m. Eastern Time on July 20, 2023.

No action is required by existing PMGM shareholders with respect to the ticker symbol or exchange listing change.



Source link